Positioning siponimod and the post-treatment gap: the unmet needs of SPMS patients in Italian real-world practice

Background: Siponimod, a selective sphingosine-1-phosphate receptor modulator was approved for patients with Secondary progressive Multiple Sclerosis (SPMS) with ongoing disease activity. However, its real-world positioning and management after discontinuation remain challenging. Objectives: To eval...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Aurora Zanghì, Giovanna Borriello, Matteo Foschi, Assunta Bianco, Elisabetta Signoriello, Maria Cellerino, Paola Sofia Di Filippo, Francesco Baldisseri, Giuseppe Romano, Alessandra Cicia, Giacomo Lus, Matilde Inglese, Massimiliano Mirabella, Carlo Avolio, Emanuele D’Amico
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	SAGE Publishing 2026-02-01
Σειρά:	Therapeutic Advances in Neurological Disorders
Διαθέσιμο Online:	https://doi.org/10.1177/17562864251399560
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!